Literature DB >> 27790734

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.

S Petta1, G Cabibbo1, M Barbara1, S Attardo1, L Bucci2, F Farinati3, E G Giannini4, F Tovoli2, F Ciccarese5, G L Rapaccini6, M Di Marco7, E Caturelli8, M Zoli2, F Borzio9, R Sacco10, R Virdone1, F Marra11, M Felder12, F Morisco13, L Benvegnù3, A Gasbarrini6, G Svegliati-Baroni14, F G Foschi15, A Olivani16, A Masotto17, G Nardone13, A Colecchia2, M Persico18, V Boccaccio19, A Craxì1, S Bruno19, F Trevisani2, C Cammà1.   

Abstract

BACKGROUND: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. AIM: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens.
METHODS: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications.
RESULTS: TTR by Kaplan-Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P < 0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies.
CONCLUSION: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27790734     DOI: 10.1111/apt.13821

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Authors:  Xavier Adhoute; Paul Castellani; Marc Bourlière
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

2.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.

Authors:  Winnie Y Zou; Kati Choi; Jennifer R Kramer; Xian Yu; Yumei Cao; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

Review 3.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

4.  The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

Authors:  Yuko Nagaoki; Michio Imamura; Hiroshi Aikata; Kana Daijo; Yuji Teraoka; Fumi Honda; Yuki Nakamura; Masahiro Hatooka; Reona Morio; Kei Morio; Hiromi Kan; Hatsue Fujino; Tomoki Kobayashi; Keiichi Masaki; Atsushi Ono; Takashi Nakahara; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Yoshiiku Kawakami; C Nelson Hayes; Daiki Miki; Hidenori Ochi; Kazuaki Chayama
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

5.  AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.

Authors:  Takao Watanabe; Yoshio Tokumoto; Kouji Joko; Kojiro Michitaka; Norio Horiike; Yoshinori Tanaka; Fujimasa Tada; Yoshiyasu Kisaka; Seiji Nakanishi; Kazuhiko Yamauchi; Hironori Ochi; Atsushi Hiraoka; Sen Yagi; Atsushi Yukimoto; Masashi Hirooka; Masanori Abe; Yoichi Hiasa
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

Review 6.  Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review.

Authors:  Page Axley; Zunirah Ahmed; Sujan Ravi; Ashwani K Singal
Journal:  J Clin Transl Hepatol       Date:  2017-12-17

Review 7.  Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.

Authors:  Maria Guarino; Anna Sessa; Valentina Cossiga; Federica Morando; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2018-06-28       Impact factor: 5.742

Review 8.  Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.

Authors:  C Nelson Hayes; Peiyi Zhang; Yizhou Zhang; Kazuaki Chayama
Journal:  Viruses       Date:  2018-09-28       Impact factor: 5.048

9.  Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals.

Authors:  Yoshihiko Tachi; Takanori Hirai; Yuko Kojima; Yoji Ishizu; Takashi Honda; Teiji Kuzuya; Kazuhiko Hayashi; Masatoshi Ishigami; Hidemi Goto
Journal:  JGH Open       Date:  2017-09-18

Review 10.  Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals.

Authors:  Thomas F Baumert; Frank Jühling; Atsushi Ono; Yujin Hoshida
Journal:  BMC Med       Date:  2017-03-14       Impact factor: 11.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.